Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

renal cell carcinoma

This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

advanced renal cell carcinoma (a form of kidney cancer). ... that supports the investigation of Keytruda-based combinations for the first-line treatment of advanced renal cell carcinoma,” said Gregory Lubiniecki, associate vice president, oncology

Latest news

  • Keytruda doubles five-year survival rate in NSCLC Keytruda doubles five-year survival rate in NSCLC

    Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer, ... renal cell carcinoma (RCC) and a host

  • BMS eyes approval for second Opdivo combo in kidney cancer BMS eyes approval for second Opdivo combo in kidney cancer

    Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... Opdivo was the first immune checkpoint

  • NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

    Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most ... Bavencio is also approved for the

  • World Castleman Disease Day World Castleman Disease Day

    Through their existing portfolio, which supports patients with iMCD, neuroblastoma, renal cell carcinoma (RCC) and oral mucositis (dryness of the mouth and throat) as a common side effect to anticancer therapy,

  • Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

    The partners had been testing Bavencio (avelumab) in untreated, advanced squamous cell carcinoma of the head and neck. ... Merck KGaA/Pfizer’s drug then picked up an approval in first-line, advanced renal cell carcinoma (RCC) last year, the most common

More from news
Approximately 9 fully matching, plus 152 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in

  • Charting a course for expansion Charting a course for expansion

    Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Deal Watch December 2015 Deal Watch December 2015

    510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Quick links

Infographics

Multimedia